Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Pharmaceutical giant AstraZeneca said a late-stage trial its dual immunotherapy regimen live cancer drug had met its primary goal.
The trial met its primary endpoint of overall survival with a single dose of tremelimumab plus Imfinzi every four weeks versus sorafenib.
Results from the a phase 3 trial showed a single dose of tremelimumab, an antibody, and Imfinzi, demonstrated a statistically significant and clinically meaningful overall survival benefit versus sorafenib as a treatment for patients with hepatocellular carcinoma, a type of liver cancer.
Imfinzi alone demonstrated non-inferior overall survival to sorafenib with a numerical trend in favour of Imfinzi and an improved tolerability profile compared to sorafenib.